609 related articles for article (PubMed ID: 27527088)
1. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
[TBL] [Abstract][Full Text] [Related]
2. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
[TBL] [Abstract][Full Text] [Related]
4. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
[TBL] [Abstract][Full Text] [Related]
5. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.
Hernandez LD; Racine F; Xiao L; DiNunzio E; Hairston N; Sheth PR; Murgolo NJ; Therien AG
Antimicrob Agents Chemother; 2015 Feb; 59(2):1052-60. PubMed ID: 25451052
[TBL] [Abstract][Full Text] [Related]
6. Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab.
Hernandez LD; Kroh HK; Hsieh E; Yang X; Beaumont M; Sheth PR; DiNunzio E; Rutherford SA; Ohi MD; Ermakov G; Xiao L; Secore S; Karczewski J; Racine F; Mayhood T; Fischer P; Sher X; Gupta P; Lacy DB; Therien AG
J Mol Biol; 2017 Apr; 429(7):1030-1044. PubMed ID: 28232034
[TBL] [Abstract][Full Text] [Related]
7. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T
J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028
[TBL] [Abstract][Full Text] [Related]
8. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
[TBL] [Abstract][Full Text] [Related]
9. Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.
Kufel WD; Devanathan AS; Marx AH; Weber DJ; Daniels LM
Pharmacotherapy; 2017 Oct; 37(10):1298-1308. PubMed ID: 28730660
[TBL] [Abstract][Full Text] [Related]
10. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
[No Abstract] [Full Text] [Related]
11. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
[TBL] [Abstract][Full Text] [Related]
12. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
[TBL] [Abstract][Full Text] [Related]
13. Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.
Lv Z; Peng G; Liu W; Xu H; Su J
Antimicrob Agents Chemother; 2015 Jul; 59(7):3726-35. PubMed ID: 25824219
[TBL] [Abstract][Full Text] [Related]
14. Bezlotoxumab for the treatment of Clostridium difficile-associated diarrhea.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2017 Jul; 53(7):385-392. PubMed ID: 28837182
[TBL] [Abstract][Full Text] [Related]
15. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.
Freeman J; Marquis M; Crowther GS; Todhunter SL; Fawley WN; Chilton CH; Moeck G; Lehoux D; Wilcox MH
J Antimicrob Chemother; 2012 Dec; 67(12):2919-26. PubMed ID: 22899803
[TBL] [Abstract][Full Text] [Related]
16. [Preclinical and clinical properties of Bezlotoxumab (ZINPLAVA
Kinoshita K
Nihon Yakurigaku Zasshi; 2018; 152(1):39-50. PubMed ID: 29998951
[TBL] [Abstract][Full Text] [Related]
17. AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge.
Guilleman MM; Stevens BAY; Van Lieshout LP; Rghei AD; Pei Y; Santry LA; Thompson B; Wootton SK
Gene Ther; 2023 May; 30(5):455-462. PubMed ID: 33608675
[TBL] [Abstract][Full Text] [Related]
18. A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.
Schmidt DJ; Beamer G; Tremblay JM; Steele JA; Kim HB; Wang Y; Debatis M; Sun X; Kashentseva EA; Dmitriev IP; Curiel DT; Shoemaker CB; Tzipori S
Clin Vaccine Immunol; 2016 Sep; 23(9):774-84. PubMed ID: 27413067
[TBL] [Abstract][Full Text] [Related]
19. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
[TBL] [Abstract][Full Text] [Related]
20. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]